Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gp96-pulsed dendritic cell vaccine (Second Affiliated Hospital of Guangzhou Medical University)
- Development stage
- Unknown
- Lead developer
- Second Affiliated Hospital of Guangzhou Medical University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intratumoral
01
Overview
This dendritic cell (DC) vaccine is an autologous cell therapy developed by the Second Affiliated Hospital of Guangzhou Medical University for the treatment of advanced solid tumors. The vaccine is produced by isolating a patient's own dendritic cells from peripheral blood and pulsing them ex vivo with heat shock protein gp96 (endoplasmin) purified from either placental tissue or the patient's own tumor. Gp96 serves as a chaperone for a broad spectrum of tumor-associated antigens and acts as a potent adjuvant by interacting with receptors such as CD91 on the surface of DCs, promoting their maturation and the cross-presentation of antigens to CD8+ T cells. The resulting activated DC vaccine is re-administered to the patient via subcutaneous or intratumoral injection to stimulate a robust, tumor-specific cytotoxic T lymphocyte (CTL) response.
- Other names
- DC cell Vaccinegp96-induced dendritic cell vaccinegp-96-induced dendritic cell vaccinegp 96-induced dendritic cell vaccine
02
Targets
LRP1 (Prolow-density lipoprotein receptor-related protein 1)MSR1 (Amyloid beta precursor protein binding family B member 3)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on gp96-pulsed dendritic cell vaccine (Second Affiliated Hospital of Guangzhou Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gp96-pulsed dendritic cell vaccine (Second Affiliated Hospital of Guangzhou Medical University).